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Hebrew University and Hadassah Medical Center, Jerusalem, IsraelAbstract Kaposi's sarcoma (KS), an angioproliferative disorder, has a viral etiology and a multifactorial
pathogenesis hinged on an immune dysfunction. The disease is multifocal, with a course ranging from
indolent, with only skin manifestations to fulminant, with extensive visceral involvement. In the current
view, all forms of KS have a common etiology in human herpesvirus (HHV)-8 infection, and the
differences among them are due to the involvement of various cofactors. In fact, HHV-8 infection can be
considered a necessary but not sufficient condition for the development of KS, because further factors
(genetic, immunologic, and environmental) are required. The role of cofactors can be attributed to their
ability to interact with HHV-8, to affect the immune system, or to act as vasoactive agents. In this
contribution, a survey of the current state of knowledge on many and various factors involved in KS
pathogenesis is carried out, in particular by highlighting the facts and controversies about the role of some
drugs (quinine analogues and angiotensin-converting enzyme inhibitors) in the onset of the disease. Based
on these assessments, it is possible to hypothesize that the role of cofactors in KS pathogenesis can move
toward an effect either favoring or inhibiting the onset of the disease, depending on the presence of other
agents modulating the pathogenesis itself, such as genetic predisposition, environmental factors, drug
intake, or lymph flow disorders. It is possible that the same agents may act as either stimulating or
inhibiting cofactors according to the patient’s genetic background and variable interactions.
Treatment guidelines for each form of KS are outlined, because a unique standard therapy for all of
them cannot be considered due to KS heterogeneity. In most cases, therapeutic options, both local and
systemic, should be tailored to the patient’s peculiar clinical conditions.
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Kaposi's sarcoma (KS) is an angioproliferative disease,
with a viral etiology and a multifactorial pathogenesis hinged
414 E. Ruocco et al.on an immune dysfunction. The name is bound to Moritz
Kaposi (1837–1902) who described three fatal cases of
multiple idiopathic pigmented hemangiosarcoma in elderly
men at the University of Vienna in 1872.1 Since then, KS has
been defined as a malignant neoplasm of blood or lymph
vessels presenting with multiple vascular nodules in the skin
or other organs. The disease is multifocal, with a course
ranging from indolent, with only skin manifestations, to
fulminant, with extensive visceral involvement.KS clinical classification
Since Kaposi’s description of the classic type clinicians
have described four distinct types. Although the classic type
remains more prevalent among elderly men of Mediterranean
origin, it has been diagnosedworldwide and typically follows a
benign course. The African endemic form of KS was first
described in 1914 and occurs predominantly among young
black men aged 25 to 40 years.2 There is also a lymphadeno-
pathic subvariant of the African form that affects children at a
mean age of 3 years.3 In the 1970s, a third form associatedwith
immunosuppressant treatment was described among recipients
of organ transplantation, patients on long-term corticosteroids
for various disorders, and patients immunosuppressed as a
result of other therapeutic regimens, including chemotherapy
(iatrogenic form).4,5 Finally, in 1981, an epidemic of KS
among young men who had sex with men in the United States
served as the harbinger of a new immunodeficiency syndrome,
subsequently identified as being associated with HIV infection
(epidemic form).6 As the HIV epidemic progressed, KS was
found almost exclusively among homosexual men.7 Due to
epidemiologic data indicating the high incidence of KS among
persons at greater risk for sexually transmitted infections, a
further independent infectious agent was proposed in the
etiology of epidemic KS.7Etiology and pathogenesis of KS
From the viral etiology hypothesis to the
HHV-8 discovery
Although the onset of KS ensues from complex and
multifactorial events, including immunosuppression,8 a
crucial role of viral agents has been supposed since the
1950s.2,3 In the 1970s, a specific role for herpesviruses was
proposed.9 Giraldo and colleagues observed herpes-type
viral particles in five of eight tissue culture cell lines from
African patients with KS10 and subsequently cytomegalovi-
rus genetic sequences were identified in those tumors.11 In
1994, a major breakthrough in the etiology of KS was
reported. Chang and co-workers identified a new human
herpesvirus, HHV-8, by representational difference analysisand detected this virus in more than 90% of KS lesions,
including those unrelated to HIV.12 Subsequently, HHV-
8 has been documented in more than 95% of KS patients of
all four types of KS.13 HHV-8, found in saliva and semen,
may spread through contact with saliva and kissing, as well
as sexual activity, similarly to what occurs with other
herpesviruses.14 The prevalence of HHV-8 antibodies in-
creases with age and shows wide fluctuations geographical-
ly. Low rates (b5%) of HHV-8 seroprevalence are reported
in North Europe and the Americas,15 high rates (35%) in
Sicily,,16 and very high (87%) in Botswana.17 The rates are
usually related to the prevalence of KS.18 Nevertheless, there
are countries, such as Brazil, Gambia, Ivory Coast, and
Thailand, with high HHV-8 seroprevalence and low
incidence of KS.19
Geographical distribution of HHV-8 variants
Phylogenetic studies performed on the well-conserved
open reading frame (ORF) 26 (minor capsid gene) allowed
the identification of eight distinctive subtypes designated as
A/C, J, K/M, D/E, B, Q, R, or N groups, which are
diversely distributed in different geographical regions. In
particular, four subtypes (B, N, Q, and R) have been found
almost exclusively among Sub-Saharan African samples,
one (D/E) has been found only within indigenous South
Asian and Polynesian (Pacific Rim) populations, and three
(A/C, J, and K) have been identified almost exclusively in
Eurasian subjects (European, United States, North Asian,
and Middle Eastern).20 Sequence analysis of the highly
variable ORF K1 region has allowed the identification of
seven major HHV-8 subtypes (A, B, C, D, E, F, and Z),
comprising each several sub-clades, whose distribution in
the world parallels that of ORF 26 variants: HHV-8 subtype
B predominates in Africa and F has been identified in
Ugandan Bantu tribe, subtype D is present in the Pacific
islands; subtype E clusters in ancient populations, like
Brazilian Amerindians, whereas A and C predominate in
Europe and the United States.21–25 It is still unclear whether
different genotypes may have different pathogenic and
tumorigenic properties associated with inverse rates of
disease progression.26–29The role of co-factors in KS pathogenesis
Pathogen-related diseases do not have the same clinical
outcome in all infected patients with a subset developing
chronic infections and a smaller subset progressing to cancer,
suggesting that cofactors are needed for the different
evolution, including genetic and environmental determi-
nants. In the current view, all forms of KS have a common
etiology in HHV-8 infection and their differences are due to
the involved cofactors.30 HHV-8 infection, in fact, can be
considered a necessary but not sufficient condition for the
development of KS because further factors (genetic,
immunologic, and environmental) are required.
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It is well known today that HHV-8 is a necessary cause
for the development of KS, but given the heterogeneous
distribution of the virus, the incidence of KS in different
populations, and the datum that only a small percentage of
HHV-8 seropositive patients develop KS, other genetic or
environmental cofactors are clearly necessary for the
development of this tumor.31–34
HHV-8, similar to other DNA oncogenic viruses,
expresses viral genes that directly or indirectly perturb p53
protein functions and thereby mediate viral oncogenesis.35
The p53 protein plays a central role in cell cycle control for
its ability to induce cell cycle arrest and DNA repair, or
senescence and apoptosis in response to a variety of stimuli
such as stress signals, genotoxic agents, hypoxia and
oncogene activation.36 The key function of p53 in
oncogenesis as tumor suppressor protein is supported by
the fact that TP53 is the most frequently mutated gene in a
variety of human cancer of diverse histologic type.37 HHV-
8 virus interferes with p53 pathway at several levels: (1) the
latency-associated nuclear antigen, encoded by ORF 73 of
the HHV-8 genome, suppresses p53 transcription and
transactivation activity, and interacts directly with the p53
protein inhibiting the ability of p53 to induce cell death35,38;
(2) the viral interferon (IFN) regulatory factor 4 (vIRF4),
encoded by ORFK10/K10.1 of HHV-8, specifically interacts
with and stabilizes murine double minute 2 (MDM2) human
homologue, a well-known negative regulator of p53 via
proteasome-mediated degradation, leading to the consequent
reduction of p53 levels and thereby concurring to the
suppression of p53-mediated apoptosis.39,40 The relevance
of the vIRF4 interference with MDM2 protein is strongly
supported by its relevance in cell cycle control.
A number of studies have shown that MDM2 is
overexpressed in several human cancers. The higher
expression levels of MDM2 are mutually exclusive in
respect to p53 mutations suggesting that they may substitute
for mutational inactivation of p53.41,42 A naturally occurring
G to T sequence variation (single-nucleotide polymorphism
309 [SNP309]) in the second promoter-enhancer region of
MDM2 gene has been shown to increase the binding affinity
of the transcriptional activator Sp1 resulting in high levels of
MDM2 protein, formation of transcriptionally inactive p53–
MDM2 complexes and alteration of the p53 pathway.43,44
These observations are consistent with an oncogenic
function for the variant SNP309. The MDM2 SNP309
polymorphism may be associated with earlier onset of breast
cancer in Li-Fraumeni patients43,45,46 and with earlier onset
of soft tissue sarcoma, diffuse large B-cell lymphoma,
colorectal cancer, and non-small cell lung cancer particularly
in women.47–49
In a recent study, a significant increase of the heterozy-
gousMDM2 SNP309 T/G genotype among white classic KS
cases was reported.50 The homozygousMDM2 SNP309 G/G
genotype in classic KS, on the other hand, was lower (9.1%)
than observed in controls (15.6%). The decreased frequencyof MDM2 SNP309 G/G genotype in cutaneous KS patients
could have several explanations including that G/G carriers
with HHV-8 infection could be at increased risk for
developing visceral KS, or highly aggressive HHV-8 related
lymphoproliferative disorders such as primary effusion
lymphoma (PEL) or multicentric Castleman’s disease.51
The analysis of seven PEL cell lines for mutations and SNPs
in 10 genes involved in apoptosis and cell cycle regulation,
including SNP309 in MDM2 and codon 31 in CDKN1A
genes has been demonstrated.52 Interestingly, three (42.8%)
Epstein-Barr virus (EBV)–negative cell lines, namely BC3,
BCBL-1 and BCP, were homozygous for SNP309 G,
suggesting a major role of this polymorphic allele in cell
transformation, particularly in the absence of EBV co-
infection. Future researches, however, are needed to
accurately address this hypothesis.
Immune deficit and risk for KS
Systemic immunodeficiency. KS prevalence is tremen-
dously higher in post-transplant and AIDS patients, being
500 times and 20,000 times, respectively, greater than in the
general population.30 The incidence of KS has changed
markedly during AIDS epidemic, particularly across the
African continent. Before the HIV epidemic KS was a
disease primarily affecting men, with extreme incidence
variation among specific populations in different geograph-
ical regions. In Uganda, from 1954 to 1960 and 1968 to
1970, KS represented 6.4% to 6.6% of all male cancer
patients, respectively, with rare female cases53,54; however,
from 1989 to 1991, KS prevalence in male cancer patients
rose to 48.6% (incidence of 30.1/100,000), becoming the
most frequently reported cancer in men, whereas prevalence
in female cancer patients climbed to 17.9% (incidence of 11/
100,000).55 Since the HIV epidemic, KS has become as
common in women as in men and has been prevalent also in
many African countries where it was almost unknown, but
where HHV-8 has been shown to be prevalent.56 These
observations point to a role for other factors in the etiology of
KS, including the possibility that different HHV-8 variants
might spread during HIV/AIDS epidemic.
Local immunodeficiency. Concerning immunity disor-
ders, systemic immunodeficiency should be considered as
well as conditions of local immune destabilization, such as
lymphedema, caused by several agents, often environmental
factors.57 In endemic KS, there is a relationship between KS
and podoconiosis (non-filarial elephantiasis) and an in-
creased prevalence of KS among rural peasants and
cultivators toiling up highland soils containing volcanic
clay minerals.58 Walking barefoot on volcanic soils exposes
pores and sweat glands in bare feet permits abrasions and
allows aluminosilicates and possibly iron oxides to be taken
up by lymphatics. The silicates can cause an obstacle to
lymph flow, inflammation of regional lymph nodes, and
disruption of the immune control in the feet and legs. As a
result, these sites become an immunocompromised district,
namely, a body region where chronic lymph stasis leads to an
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opportunistic infections (parasitic, bacterial, fungal) or
tumors, as paradigmatically KS is. The link between the
impairment of lymph circulation and regional immune
dysfunction in classical KS was first proven in 1984.59 KS
appeared on a lymphedematous leg of a patient with altered
lymph drainage and lack of cell immune response confined to
the lymphedematous limb. Intradermal skin tests to common
antigens performed on the four limbs (forearms and legs)
revealed no immune responses on the affected limb versus
normal or even strong responses on the three unaffected
limbs.59 Five years later, the same patient presented with
lymphedema and new KS lesions on the other leg. On this
occasion, skin tests were negative on both legs, whereas
normal responses were still observed on the forearms.60 Two
years later, KS lesions also appeared on both the forearms: At
this time, skin tests were negative on all four limbs.60 A
lymphologic and immunologic investigation performed in
patients with classical KS sensitized with dinitrochloroben-
zene proved that the affected limbs presented concomitant
alteration of the lymph drainage and of the immune
response.61 The role of chronic lymphedema in facilitating
the onset of KSwas stressed in an unusual localization (penis)
of the classical form62 and even in the epidemic AIDS-related
type.63 Although rarely emphasized in HIV-related KS, a
variable degree of lymphedema (overt or subtle, a sort of
microlymphedema) of the KS-involved areas is somewhat
common in homosexual men and has a wide anatomic
distribution, often without notable lymphadenopathy.64,65
Also a localized traumamay be responsible for facilitating the
onset of KS lesions selectively on the traumatized area.66,67
Environmental cofactors and risk for KS
In cancer pathogenesis, the possibility exists that
following an initial stable, genetic damage (initiation
event), a transient post-initiation insult (promotion event),
nonsufficient by itself to induce a cancer, could contribute to
increase cancer incidence.68 Viruses, like chemicals, can act
both as initiators as well as promoters, depending on their
prevalent effects either mutagenic (eg, herpesviruses) or
epigenetic (eg, papillomaviruses).69–71
Viruses can interact with several co-carcinogens, which
may act simultaneously or sequentially, continuously,Table 1 Multifactorial etiopathogenesis of Kaposi’s sarcoma a
KS variant Herpesvirus Factors affecting immu
Classic HHV-8 Aging-related T-cell im
Endemic HHV-8 Environment (parasites
Drugs (antimalarials)
Iatrogenic HHV-8 Steroids; immunosuppr
Epidemic HHV-8 HIV infection of T-cell
quinine and heroin
ACE, angiotensin-converting enzyme; HHV, human herpesvirus; KS, Kaposi’s
a Modified from Haverkos.57repeatedly, or occasionally. These co-carcinogens may act
directly on the potential cancer cell or indirectly by affecting
other tissues of the host. KS can represent a good model of
interaction between different oncogenic factors, useful to
identify their role and their mechanisms.8,72 The role of
cofactors can be attributed to their ability to interact with
HHV-8, to affect the immune system, or to act as vasoactive
agents (Table 1).57
In AIDS-related KS, for instance, the use of large
quantities of nitrite inhalants among gay men with AIDS
was strongly associated with KS onset. Several plausible
biologic mechanisms of action have been proposed for
nitrites and their metabolites, such as cholesteryl nitrite and
nitrosamines to be carcinogenic. Nitrite inhalant use might
also contribute to the development of KS through immune
suppression or affecting small blood vessels.73,74
Drugs as environmental cofactors for risk for KS: Facts
and controversies. Some drugs proved to be associated
with KS pathogenesis due to their immunomodulatory and
proangiogenic effects. Quinine and its analogues, 4-amino-
quinolines, are drugs used for many years in malaria
treatment. The link between these drugs and KS is based
on a series of clues that take into account the geographical
distribution and incidence of KS in patients taking these
drugs. In fact, HHV-8 seropositivity and KS have a high
prevalence in areas such as sub-Saharan Africa, Italy, and
Greece and low in northern Europe and Asia, which reflects
the same pattern of distribution of malaria.75,76 There are
regions of the world, such as Brazil, Gambia, Ivory Coast,
and Thailand, with high HHV-8 seroprevalence where KS
and malaria are rare and the use of quinine derivatives is low,
thus confirming the possible association of these drugs with
KS development. In several regions of sub-Saharan Africa,
despite the widespread resistance of Plasmodium to
quinolines and the availability of more efficacious anti-
malarial drugs, quinine and its analogues continue to be
widely used in the treatment of malaria. In fact, since 2009,
31 African countries have recommended quinine as second-
line treatment for uncomplicated malaria, 38 as first-line
treatment of severe malaria, and 32 for treatment of malaria
in the first trimester of pregnancy.77 In most of Africa,
quinine is still used as monotherapy, contrary to recommen-
dations by the World Health Organization (WHO).77ne system functions Vasoactive agents
mune deficiency ACE inhibitors
, diet, herbs) Aluminosilicates and iron oxides
taken up by lymphatics
essants ACE inhibitors
s; Nitrite inhalants
sarcoma.
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management of malaria in sub-Saharan Africa and other
malaria endemic areas, and its use in routine practice may not
be restricted to the stated WHO recommendations. In
Cameroon, quinine has continued to be used as first-line
therapy, with 45% of adults receiving oral quinine for
uncomplicated malaria.78 Recent surveillance data from
sentinel sites in Uganda showed that quinine was prescribed
for up to 90% of children younger than age 5 years with
uncomplicated malaria.79 Furthermore, this drug and its
analogs are widely distributed to healthy children as
preventive treatment (prophylaxis campaigns). The still
widespread use of antimalarials might contribute to the
high incidence of KS in the geographic areas where both KS
and malaria are endemic. In fact, KS and its causative agent,
HHV-8, have distinctive geographic distributions that are
largely unexplained. For this reason, it has been put forward
an “oncoweed hypothesis,” which suggests that environ-
mental cofactors (such as some plants and natural products
deriving from them) present in KS endemic regions may
cause frequent reactivation of HHV-8 in infected subjects,
thus leading to increased viral shedding and transmis-
sion.33,80 Conversely, it has been hypothesized that quinine
and its derivatives might better explain the epidemiology of
KS than oncoweeds. This oncodrug hypothesis, specifically
hints at quinine and its derivatives.81 In fact, it is worth
noting that quinine, chloroquine, and hydroxychloroquine
may affect the effectiveness of the immune response, being
immunosuppressive drugs. It is well known that chloroquine
and hydroxychloroquine are extensively used in the
treatment of autoimmune diseases such as lupus erythema-
tosus and rheumatoid arthritis.82 The immune-suppressive
properties of these drugs may produce deleterious effects in
the presence of viral infections or immunizations. For
example, a randomized controlled trial to evaluate the
antibody response of freshman veterinary students to
intradermal human diploid-cell rabies vaccine administered
concurrently with chloroquine have demonstrated that this
drug taken in the dose recommended for malaria prophylaxis
can reduce the antibody response to primary immunization
with rabies vaccine.83 Incidentally, one could reasonably
think that the unusually severe course run by the Spanish flu
pandemic of 1918–1919 could have been facilitated by the
documented large administration of quinine in flu patients,
because at the time, quinine was considered the “specific”
remedy for fever attacks.84
Quinine is also used to “cut” heroin, which contributes to
the widespread use of the drug among heroin addicts. In
AIDS-related KS, drug addicts represent one of the main
populations at risk; in these individuals, the use of quinine
combined with heroin can pave the way for the onset of KS
due to the interrelated anti-inflammatory and immunosup-
pressive effects of the two drugs.85
Another category of drugs, angiotensin-converting en-
zyme (ACE) inhibitors, have been widely associated with
classic and iatrogenic KS onset. Several cases reported in theliterature would indicate that ACE inhibitors might act as a
trigger for the development of KS.86,87 In fact, ACE
inhibitors have immmunomodulatory effects. The immuno-
modulatory action of ACE inhibitors has been attributed to
several mechanisms, including: (1) inhibition of the
production of pro-inflammatory cytokines such as tumor
necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, and IL-12
produced by activated monocytes and dendritic cells, (b)
antiproliferative activity, (c) inhibition of free radicals, (d)
inhibition of metalloproteases and, (e) elevation of immu-
nomodulatory prostaglandins.88 Suppression of ACE itself
may explain immune alteration (possible immunosuppres-
sion) because ACE has been shown to be involved in
immune function and to be up-regulated in inflammatory
conditions. Furthermore, ACE inhibition enhances angio-
genesis through the activation of the B2-receptor pathway.
This proangiogenic effect may be associated with the up-
regulation of endothelial nitric oxide synthase (eNOS)
expression, but would be independent by the vascular
endothelial growth factor (VEGF) pathway.89 Other studies,
however, have confirmed that the same eNOS up-regulation
would be able to stimulate the VEGF pathway,90 or to
stimulate angiogenesis through the production of pro-
inflammatory cytokines or activation of cyclooxygenase-2.91
Evaluating the role of cofactors in the outbreak of KS is
not an easy task. For example, some contradictory data make
it difficult to assess the relationship existing between
antimalarial drugs and KS (Table 2). Chloroquine and
hydroxychloroquine, quinine analogs, have recently being
considered potential anticancer agents as well as chemosen-
sitizer when used in combination with anticancer drugs, such
as 5-fluorouracil in colon cancer cells or topotecan in lung
cancer cells, possibly by inhibiting autophagy-dependent
resistance to chemotherapy.92,93 Autophagy is an evolution-
arily conserved cell survival pathway that has been
implicated as a potential mechanism of resistance to
anticancer agents. In fact, it can promote cell survival in
the face of stress induced by chemotherapeutic agents by
breaking down cellular components to generate alternative
sources of energy. Disruption of autophagy with chloroquine
induces the accumulation of ubiquitin-conjugated proteins,
stimulating apoptosis in several cancer cells.94 Chloroquine
and hydroxychloroquine also inhibit angiogenesis and
production of proinflammatory cytokines such as IL-1β,
IL-6, IL-18, VEGF, fibroblast growth factors (FGF)-2,
TNF-α, transforming growth factor-β and IFN-β. Most
cytokines are involved in the reactivation of the HHV-8 lytic
cycle and induction of the microenvironment necessary for
lesion formation, which is characterized by a triad of
inflammation, angiogenesis, and production of cytokines
and chemokines. Thus, these drugs can counteract the
molecular targets by which HHV-8 is able to cause the
disease and indirectly they can inhibit the action of the
virus.95,96
Even more complex is the evaluation of the direct effects
exerted by antimalarial drugs on HHV-8. In fact, chloroquine
Table 2 Controversies concerning role of antimalarials and
ACE inhibitors in KS onset: Pro and con
Favoring effect Impeding effect
High prevalence of KS in
malarial areas with
widespread use of quinine
and its derivates18
Quinolines are potential
anticancer agents alone or in
combination with other
antineoplastic drugs:
inhibition of autophagy and
apoptosis92–94
Low prevalence of KS in areas
where malaria is rare and
quinine derivates are rarely
used19
Lysosomotropic effects of
quinolines inhibit pH-
dependent steps of viral entry
and replication99–101
Use of quinine to “cut” heroin
in drug addicts affected by
AIDS-KS85
Quinolines inhibit
angiogenesis, hallmark of KS
pathogenesis95
Well-known
immunosuppressive
properties of quinine and its
derivatives, largely used in
the treatment of autoimmune
diseases (SLE, DLE,
rheumatoid arthritis)82
Quinolines inhibit production
of pro-inflammatory
cytokines, involved in HHV-
8 lytic cycle reactivation96
Antimalarials indirectly
encourage the onset of KS,
through their inhibitory
effect on TNF-α
expression103
Antimalarials indirectly
prevent the onset of KS,
through their inhibitory effect
on TNF-α expression102
Chloroquine can reduce the
antibody response to primary
immunization83
ACE inhibitor intake can
induce KS86,87
ACE inhibitor intake can
protect from KS104
ACE, angiotensin-converting enzyme; DLE, discoid lupus erythemato-
sus; HHV, human herpesvirus; KS, Kaposi’s sarcoma; SLE, Systemic
lupus erythematosus; TNF, tumor necrosis factor.
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stances that are selectively taken up into lysosomes; owing to
their accumulation, these drugs are able to increase the
intracellular pH and inhibit pH-dependent steps of duplica-
tion of several bacteria (Enterobacterium agglomerans,
Staphylococcus aureus) and replication of viruses including
members of the flaviviruses, retroviruses, coronaviruses and
herpesviruses through blockade of bacterial and viral entry
via inhibition of endosomal acidification.97–100 Several
studies have shown that the same HHV-8 entry is blocked
by inhibition of acidification of endosomes.101
Also problematic is the role of TNF-α; in fact, this factor
seems to play a key role for lytic cycle reactivation of the
virus (HHV-8 itself stimulates TNF-α production) and to
create the ideal environment for the genesis of the disease.102
Antimalarial drugs seem able to exert a protective effect by
inhibiting the production of TNF-α through inhibition of
toll-like receptors; however, some studies have shown the
outbreak of KS in patients taking TNF-α blockers such as
infliximab; these cases have questioned the role of this factorin the genesis of the disease, especially regarding the role of
its production or inhibition in the reactivation of HHV-8 lytic
cycle and, in general, in KS pathogenesis.103
Concerning ACE inhibitors, some studies have suggested
a protective role played by these drugs as a result of the
improvement or regression of KS lesions in patients who
were administered ACE inhibitors.104 The matter is
controversial because opposite mechanisms of action,
protective or inducing, have been alleged (Table 2).105–107
Based on these assessments, it is possible to hypothesize
that the role of cofactors in KS pathogenesis can move
toward an effect either favoring or inhibiting the onset of the
disease depending on the presence of other agents modulat-
ing the pathogenesis itself, such as genetic predisposition,
environmental factors, drug intake, or lymphatic system
disorders. It is possible that the same agents may act as either
stimulating or inhibiting cofactors based on the patient’s
genetic background and their variable interactions.
Treatment guidelines
Due to the KS heterogeneity, there are no standard
therapeutic guidelines and several different therapeutic options
are available for KS treatment. Treatment decisions must take
into consideration the extent and the rate of tumor growth,
patient’s symptoms, immune system conditions, and concur-
rent HIV-related complications. The best therapeutic results
are obtained in the classic KS with only local treatment.
Iatrogenic KS usually regresses after withdrawal of the
“culprit” drug(s). Endemic KS may require a systemic therapy
with cytostatic agents, which results in a variable outcome
depending on the extent and severity of the disease. Epidemic
KS prevalence has decreased dramatically since the introduc-
tion of highly active anti-retroviral therapy (HAART).
Therapeutic options can be distinguished in two groups:
local and systemic therapy.Local therapy
Local therapy allows for a safe, cost-effectiveness
approach and is reserved for patients with minimal cutaneous
disease or for nonresponders to systemic therapy who have
rapidly progressive disease, as palliative therapy. Intrale-
sional vinblastine, oral etoposide, cryotherapy with liquid
nitrogen, and excisional surgery may be feasible options.
Alitretinoid gel 0.1% (9-cis-retinoic acid) may be applied
two to four times daily in the affected areas. The overall
response rates (ORRs) range between 35% and 50% with
cutaneous reactions.Electrochemotherapy in the treatment of KS
Electrochemotherapy (ECT) is an emerging treatment for
cutaneous lesions of different tumor types. The combination
of chemotherapy and electroporation enhances drug uptake
419KS etiopathogenesis and treatmentinto tumoral cells. Twenty-three patients with histologically
confirmed unresectable KS, not treatable by radiotherapy or
intralesional vincristine therapy, were successfully treated
according to the European Standard Operating Procedures of
Electrochemotherapy guidelines. In particular, a response to
the first ECT session was obtained in all patients, with a
complete response in 14 (60.9%) of 23 patients. After a
median follow-up of 1.5 years, 16 patients maintained the
response. The overall survival rate was 74.4% at 2 years.108
Radiotherapy is effective and often represents the best
local treatment for palliation of pain, bleeding or edema, with
response and complete remission rates of more than 90% and
70%, respectively. For patients with far advanced disease a
single dose of 8 Gy is preferable.109
Systemic therapy
HAART
HAART is indispensable in the treatment of epidemic KS
in all patients, alone or in combination with systemic
chemotherapy and local therapy. Some antiretroviral drugs
such as foscarnet, ganciclovir, cidofovir, and adefovir are
alleged to have anti-HHV-8 activity. In patients with limited
cutaneous lesions (T0 early-stage disease and/or slowly
proliferating disease) an effective HAART regimen may
represent the first step of therapy for KS, with an ORR of
66% to 86% and a complete remission rate of 35%. KS
lesions typically start to decrease and disappear completely
within a few weeks or months. Frequently, KS may flare
dramatically following the initiation of HAART, which
seems to be a manifestation of the immune reconstitution
inflammatory syndrome (IRIS), that occurs in HIV-positive
patients with initial low CD4 counts and an incontrollable
viral load. At present, HAART alone may represent the first-
line therapy for T0 and T1 slowly progressive disease.
HAART with concomitant chemotherapy is indicated for
visceral and/or rapidly progressive disease, whereas HAART
after systemic chemotherapy may be effective as anti-KS
therapy after debunking chemotherapy (ORR 91%).110,111
Systemic chemotherapy
Systemic chemotherapy is reserved for patients who do
not respond to HAART and/or have widespread, symptom-
atic, rapidly progressive, life-threatening disease with
visceral involvement or an IRIS-associated flare. Several
single-agent therapies have been reported to be active in
AIDS-related KS (vincristine, vinblastine, vinorelbine,
etoposide, teniposide, adriamycin, epirubicine, bleomycin,
docetaxel, and paclitaxel), with ORRS ranging between 30%
and 70%, although most were partial responses. Liposomal
anthracyclines (doxorubicin or daunorubicin) are now
considered as first-line therapy for patients with advanced
AIDS-KS.112
Paclitaxel, a cytotoxic agent that exerts its antitumor
activity by polymerizing microtubules and inhibiting cell
division, is reserved for patients with recurrent or refractoryAIDS-related KS after first-line chemotherapy. Intravenous
paclitaxel (100 mg/m2 given every 2 weeks as a 3-hour
infusion) is associated with a response rate of 59% and
duration of sustained response of 10 months.
High-dose IFN-α allows obtaining complete and partial
response rates between 20% and 40%, if the CD4 + count is
greater than 200/mm3.
Target therapy
Current understanding of KS as a convergence of immune
evasion, oncogenesis, inflammation, and angiogenesis has
prompted investigators to develop a target therapy based on
antiangiogenic agents, metalloproteinase, and inhibitors of
cytokine signaling. This therapy may be an effective strategy
for patients with epidemic KS that progressed despite
chemotherapy and/or HAART. Irinotecan (CPT-11), a
semisynthetic camptothecin derivative converted by decar-
boxylation into a biologically active form SN-38 (7-ethyl-10-
hydroxycamptothecin), belongs to a recently established
class of anticancer agents with a cytotoxic mechanism
targeting the cellular enzyme DNA topoisomerase I. The
model of fibroblast growth factor-β–induced angiogenesis in
mouse cornea suggests that irinotecan may be active also in
KS. Data from a GICAT (Gruppo Italiano Cooperativo AIDS
e Tumori) Phase II study show that intravenous CPT-11 (150
mg/m2 day 1; 10 mg/m2 every 21 days) plus HAART
including protease inhibitors is active and well tolerated in
HIV-infected patients with KS relapse or progression during
HAART.113
Matrix metalloproteinases (MMPs), constitutively over-
expressed in KS cells, are a family of zinc-dependent
endopeptidases involved in the degradation of collagen IV,
the major component of basement membranes, that facilitate
tumor invasion and metastases. Phase II trial data have
shown that 50 mg COL-3, an MMP inhibitor that blocks in
vitro activated neutrophil gelatinase and the expression of
MMPs in human colon and breast cancer cell lines in a dose-
dependent manner, administered orally once daily, produces
a significant decline in MMPs levels. The ORR is 41%, with
median duration of response of 52 weeks.114 Thalidomide
(100 mg/day for 12 months) has been shown to block TNF-α
production and to inhibit basement membrane formation and
intercellular adhesion molecules. The inhibition of vascular
endothelial cell proliferation induced by thalidomide occurs
in association with a marked decrease in the activity of the
transcription factor SP1, which is involved in the extracel-
lular matrix gene expression and moderate inhibition of
nuclear factor-κB activation in nuclear extracts.115 IL-12, a
cytochine that enhances type 1 immunity, can down-regulate
a constitutively active G protei-coupled receptor that is
encoded by HHV-8. According to the preliminary results
from a Phase I study on the combination of IL-12 plus
liposomal doxorubicin and HAART, remission was obtained
in a substantial percentage of patients with advanced KS.116
Oral imatinib mesylate (300 mg twice daily) inhibited
activation of the platelet-derived growth factor and c-kit
420 E. Ruocco et al.receptors, important targets in mediating the growth of
AIDS-related KS.117Conclusions
In the latest decades, the pathogenesis of KS has been
greatly elucidated and new etiologic factors have been
described, which has facilitated the development of more
effective therapeutic approaches. Many aspects of KS still
remain unsolved, and further studies are needed on the matter.References
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